Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

EGFR Inhibitor

Therapeutic area intelligence for EGFR Inhibitor with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 6
Catalysts: 0
Companies: 2

Companies

AstraZeneca →

Hetero Labs Ltd →

Assets

Recent signals(6)

ClinicalAugust 5, 2026

YH32364 Trial Targets EGFR Overexpressing Solid Tumors in Advanced Cancer Patients

A clinical trial is underway to evaluate the efficacy of YH32364 in patients with locally advanced or metastatic EGFR overexpressing solid tumors.

RegulatoryAugust 2, 2026

FDA Accepts Supplement for Lazertinib Mesylate by Janssen Biotech

The FDA has accepted a supplemental application for Lazertinib Mesylate (NDA219008) from Janssen Biotech.

RegulatoryJuly 18, 2026

Apotex submits ANDA for Afatinib Dimaleate, FDA review in progress

Apotex has submitted an Abbreviated New Drug Application (ANDA) for Afatinib Dimaleate, currently under FDA review.

StrategyJuly 18, 2026

FDA Grants Approval for Afatinib Dimaleate ANDA210750

The FDA has granted approval for the Abbreviated New Drug Application (ANDA) 210750 for Afatinib Dimaleate submitted by Hetero Labs Ltd.

StrategyJuly 14, 2026

AstraZeneca licenses novel EGFR inhibitor Zegfrovy for lung cancer

AstraZeneca has secured an exclusive global license for Zegfrovy, an oral EGFR inhibitor for lung cancer.

RegulatoryJuly 11, 2026

FDA Accepts Supplement Application for LAZCLUZE (Lazertinib Mesylate)

The FDA has accepted the supplemental application for LAZCLUZE, an EGFR inhibitor.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.